Small pyridine and soraphinist: good effect against liver cancer

Figure 1 There are currently two main ways to combat solafinib resistance: first, by choosing other drugs as second-line treatments, such as regorafenib, which is used in the liver after the use of sorafinib. Second-line therapeutic drugs for cell carcinoma; second, the effects of solaphonyl on tumor growth inhibition and apoptosis can be enhanced by a recent study that found that the natural drug soramine is used in association with soralfinium.
Figure 2 Cell Suppression Experiment As shown in Figure II, the inhibition of soraphinib on liver cancer cells (PRF-PLC-5, HCC-Lm3) was significantly enhanced by the association of soramine and soraphinib, in which THE PRF-PLC-5, Sorafinib (SORA) single-use IC50 was 14.52μM, while Sorafinib and For liver cancer cell HCC-Lm3, soraphine (SORA) single-use IC50 is 21.29 m, and Soraphini and IC50 for small niacin (SORA-BBM) IC50 is 8.442 m.
toxic effects on normal liver cells (HL-7702), the co-use is comparable to the toxicity of sorafeini monous, showing that the co-use also has better safety.
3 cell cycle-related experiments Further cell cycle-related experiments show that cyclin D1, Cdk4, Cdk6 and other proteins can regulate the cell cycle, so that cancer cells more in the G0/G1 stage.
4 apoptosis-related experiments show that (Figure 4), small pyridine has significant apoptosis-promoting activity.
diagram V path-related experiments As downstream molecules of carcinogenic tyrosine kinases (RTKs), STAT3 is highly expressed in a variety of solid tumors and plays an important role in the occurrence and development of tumors.
and numerous studies have shown that the activation of STAT3 signals is closely related to the emergence of drug resistance in a variety of targeted treatments, such as EGFR inhibitor erlotinib and angiogenesic inhibitor sorafinib.
studies have shown that pyridine can increase the sensitivity of pancreatic cancer cells to gyfeitinib by inhibiting STAT3 signaling.
this, the researchers further explored whether cytoamine could be used on STAT3 to increase soraphine's sensitivity to cancer cells.
, as shown in Figure V, the researchers used immunoprinting experiments to verify the inhibition of stAT3 in liver cancer cells.
results showed that small pyridine can dose-dependent inhibit IL-6-mediated STAT3 tyrosine 705-bit phosphorylation, and can reduce STAT3 nuclear transfer.
, phosphonamide can also effectively reduce the basic phosphatization of STAT3 tyrosine 705 bits in liver cancer cells.
further studies have confirmed that soramine can enhance Soraphini's sensitivity to liver cancer cells by targeting STAT3.
, it can be seen that the use of cytoamine and soraphinist has a very broad application prospects.
is essential to address the problem of soraphine resistance by regulating cell cycles, promoting tumor apoptosis, and STAT3 targeting.
images from Reference 1 Reference: 1. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells,2020; 2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; 3. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma. 2019.